Skip to content

CEPO CEPO Forward Sale Securities Liability

Forward Sale Securities Liability at other companies

CEP
Cantor Equity Partners II, Inc. Class A Ordinary ShareCEPT
$4.61M
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
$309M
CEP
Cantor Equity Partners II, Inc. Class A Ordinary ShareCEPT
-$1.63M-241%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+42.1%
Esperion Therapeutics logo
Esperion TherapeuticsESPR
$210.43M-11.9%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$62.08M-1.1%

Other financials

Income statement

See full
Operating income-$316.9K-64.6%
Net income-$4.2M-519%
EPS (diluted)-$0.01

Balance sheet

See full
Cash & equivalents$25.0K-90.9%
Total equity-$22.8M-713%
Total assets$209.6M+4.0%

Cash flow

See full
Operating cash flow$52.6K

Valuation

See full
Market cap$225.17M-10.4%

Returns & leverage

See full
Return on equity-77.6%
Current ratio0.2×

Where this comes from

Reported directly by CEPO in its filing.

Tagged under the XBRL concept cepo:ForwardSaleSecuritiesLiability.

The official record: CEPO’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CEPO's forward sale securities liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CEPO's forward sale securities liability?
CEPO (CEPO) reported forward sale securities liability of $18.9M in Q1 2026.
What does forward sale securities liability mean?
This liability represents the obligation arising from forward sale agreements involving the company's equity or debt securities. It reflects the financial commitment to deliver securities at a future date under predetermined terms. This metric is critical for assessing the company's future dilution risk and potential cash outflows related to financing arrangements.